Page 444 - شرور شركات الأدوية
P. 444
ﴍور ﴍﻛﺎت اﻷدوﻳﺔ
(4-3) Rothwell PM. Subgroup analysis in randomised controlled tri-
als: importance, indications, and interpretation. The Lancet. 2005;
365(9454):176–86. Available at: http://apps.who.int/rhl/Lancet_365-
9454.pdf.
(6-1) Moynihan R. The making of a disease: female sexual dysfunction.
BMJ. 2003;326(7379):45–47. Available at: http://www.ncbi.nlm.nih
.gov/pmc/articles/PMC1124933/table/TN0x95f06b0.0x98eca30/.
(6-2) http://zyprexalitigationdocuments.com/%5Cdocuments%5CConfid
entiality-Challenge%5CDocschallenged-in-10-3-list%5C145-
ZY200187608-7614.pdf.
(6-2) http://zyprexalitigationdocuments.com/%5Cdocuments%5CConfid
entiality-Challenge%5CDocschallenged-in-10-3-list%5C145-
ZY200187608-7614.pdf.
(6-2) http://zyprexalitigationdocuments.com/%5Cdocuments%5CConfid
entiality-Challenge%5CDocschallenged-in-10-3-list%5C145-
ZY200187608-7614.pdf.
(6-2) http://zyprexalitigationdocuments.com/%5Cdocuments%5CConfid
entiality-Challenge%5CDocschallenged-in-10-3-list%5C145-
ZY200187608-7614.pdf.
(6-6) Drug Industry Document Archive [Internet]. Available at: http://dida
.library.ucsf.edu/pdf/vou38h10.
(6-7) http://pogoblog.typepad.com/pogo/gw-attachmente.html.
(7-1) 15 August 2012, http://uk.finance.yahoo.com/echarts?s=GSK.L#
symbol=GSK.L;range=1y.
444
